Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Income from continuing operations attributable to Valeant: 0.42
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.
- Adjusted EBITDA (non-GAAP) of $861 Million
2017 Guidance
2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75 billion from $3.55 - $3.70 billion
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
